

Fosfomycin I.v. for Treatment of Severely Infected Patients

NCT02979951

Status	RECRUITING
Sponsor	Infectopharm Arzneimittel GmbH
Enrollment	1,000 participants

Key Eligibility Criteria

Inclusion (4)

- Male or female patients aged e 18 years
- Treatment with fosfomycin according to the (national) Summary of Product Characteristics (SmPC) of fosfomycin i.v.
- Patients with osteomyelitis, complicated urinary tract infection, nosocomial lower respiratory tract infection, bacterial meningitis/central nervous system infection, bacteraemia/sepsis, skin and soft tissue infection, endocarditis or other infection, each as far as covered by the respective nationally relevant SmPC
- Written informed consent of the participant (or person in charge in case of patients incapable of giving consent)

Exclusion (10)

- Previous documentation of the patient in the present study
- Patients participating in an interventional clinical trial
- Patients with known hypersensitivity to fosfomycin or any of the excipients
- Terminally ill patients
- Patients with "do not resuscitate order"

... and 5 more (see full listing online)

Locations (50 total)

Landeskrankenhaus Hall - Tirol Kliniken, Hall in Tirol, Austria
A.ö. Bezirkskrankenhaus, Reutte, Austria
AKH Wien, Universitätsklinik für Innere Medizin 1, Vienna, Austria
... and 47 more locations